Novo Nordisk hits record highs as study shows Wegovy treatment cut the risk of heart issues by 20%

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: Only post material that’s relevant to the topic being discussed. Avoid profanity, slander or personal attacks

directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc.

Health Health Latest News, Health Health Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Novo's weight-loss drug Wegovy cuts risk of heart disease by 20% - trial dataNovo Nordisk's obesity drug Wegovy has shown a clear medical benefit, reducing the risk of heart disease by 20% according to a large late-stage study. The positive results have boosted the Danish drugmaker's hopes of repositioning Wegovy as more than just a lifestyle drug.
Source: Reuters - 🏆 2. / 97 Read more »

Weight-Loss Drug Wegovy Lowers Major Heart Disease Risk By 20% According To Trial Data—Novo Nordisk Shares SurgeNovo Nordisk's shares rose by more than 16% on Tuesday, as the results of the trial exceeded investor expectations. The weight-loss drug Wegovy lowers the risk of 'adverse cardiovascular events' by 20%, according to data from a major trial shared by the drug's maker Novo Nordisk Tuesday, causing the company's shares to surge.
Source: Forbes - 🏆 394. / 53 Read more »